Genzyme: 15 years of cell and gene therapy research.
Finding solutions for patients with unmet needs is at the heart of Genzyme's innovative medical research. While small molecules and enzyme-replacement therapies have made significant strides in improving patients' quality of life and expectancy, the solutions to many conditions, such as heart disease or CNS diseases, rely on the capacity of the body to regenerate cells. Cell and gene therapy lend themselves well to providing solutions for these illnesses with no current cure, by harnessing the body's natural ability to heal. Promising research in these fields continues to evolve and constitutes a long-term investment in addressing serious unmet medical needs in various therapeutic areas. Over the past 15 years, Genzyme has established itself as a pioneer in shaping the research and commercial application of cell and gene therapy. Genzyme's first commercially available innovative cell therapies--Carticel and Epicel--have provided a solid foundation to move into new, cutting-edge areas.
De Bie
Caroline
C
Genzyme Corporate Affairs Europe, Ikaroslaan, Belgium. caroline.debie@genzyme.com
D001145:Arrhythmias, Cardiac / Q000628:therapy; D035843:Biomedical Research; D002318:Cardiovascular Diseases / Q000628:therapy; D004345:Drug Industry; D015316:Genetic Therapy; D006801:Humans; D015603:Keratinocytes / Q000166:cytology; D008268:Macular Degeneration / Q000628:therapy; D010300:Parkinson Disease / Q000628:therapy; D044968:Regenerative Medicine; D016038:Skin Transplantation